Resveratrol prevents development of eosinophilic rhinosinusitis with nasal polyps in a mouse model

Kim, S. W.; Kim, D. W.; Khalmuratova, Roza; Kim, J. H.; Jung, Myeong Hee; Chang, Dongwoo; Shin, Eui‐Cheol; Lee, H. K.; Shin, Hyun Woo; Rhee, Chae‐Seo; Jeon, Sea‐Yuong; Min, Yang Gi

doi:10.1111/all.12132

Cited by 40 publications

(33 citation statements)

References 25 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, a large body of recent reports has verified the health-promoting bioactivity of RSV333435363738. As one of its many effects, RSV has been reported to have a therapeutic effect on nasal polyps639. However, the administration of RSV is limited by its very low aqueous solubility4041.…”

Section: Discussionmentioning

confidence: 99%

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Lee

Park

Huh

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Resveratrol (RSV) has been shown to effectively suppress chronic rhinosinusitis with nasal polyps in a mouse model; however, when locally administered to the sinonasal cavity, bolus RSV is limited by low drug bioavailability owing to its low aqueous solubility and relatively rapid clearance from the administration site. To address this limitation, we propose mucoadhesive nanostructured microparticles (PLGA/PEG NM) as a potential carrier for the sinonasal delivery of RSV. In this study, PLGA/PEG NM released RSV in a sustained manner. Owing to the enlarged specific surface area of the nanostructures, PLGA/PEG NM had synergistically enhanced mucoadhesiveness and thus showed improved in vivo retention properties in the sinonasal cavity. Therefore, when tested in a mouse nasal polyp model, PLGA/PEG NM mitigated polyp formation and restored epithelial integrity better than the control treatments. The therapeutic effect was similar at half the dose of PLGA/PEG NM, suggesting improved local bioavailability of RSV in the sinonasal cavity.

show abstract

Section: Discussionmentioning

confidence: 99%

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Lee

Park

Huh

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Given our previous experience with a mouse model of eosinophilic CRS, we do not attribute the inadequate harvest to a technical problem. 19,20 We found that mechanical injury of the murine nasal mucosa exposed the bone and triggered neo-osteogenesis and formation of bony synechia (Fig. 2).…”

Section: Discussionmentioning

confidence: 91%

“…and ). Given our previous experience with a mouse model of eosinophilic CRS, we do not attribute the inadequate harvest to a technical problem …”

Section: Discussionmentioning

confidence: 99%

Establishment and verification of a mouse model of nasal wound healing

Joo

Jeon

et al. 2019

The Laryngoscope

View full text Add to dashboard Cite

Objectives Poor wound healing as reflected by the development of synechia and osteitis after endoscopic sinus surgery may trigger disease recurrence. Animal models provide insights into the pathogenesis of poor wound healing and may aid in the development of new therapeutics. Here, we established a mouse model of nasal wound healing and confirmed its utility. Study Design Animal study. Methods Unilateral intranasal wounds were induced using a small interdental brush in 6‐week‐old C57BL/6 mice. Forty‐five mice were divided into three groups (each n = 15): one control and two experimental groups (intranasal vs. intraperitoneal dexamethasone). Mice were sacrificed on days 2, 14, and 28 after injury (each n = 5). Serial changes in nasal wound histopathology were described, and intergroup differences were analyzed. Results On day 2, mucosal detachment, hemorrhage, and exudate were observed. On day 14, synechiae featuring neo‐osteogenesis (bone lacunae, osteoblasts, and multinucleated osteoclasts) between the septum and the maxilloturbinate were prominent, followed by wound maturation on day 28: fewer lacunae and smaller osteoblasts. Macrophages were evident only on day 2, and lymphocytes were predominant on day 28. The amount of exudate on day 2 and the synechial area on day 28 were significantly reduced in mice that received dexamethasone systemically compared with control mice, with similar trends in those treated intranasally. Conclusion Our mouse model of nasal wound healing was characterized by the development of bony synechia and neo‐osteogenesis, not soft‐tissue synechia. The model may be useful in the assessment of novel therapeutics to prevent those wounds. Level of Evidence NALaryngoscope, 129:E266–E271, 2019

show abstract

“…Kim et al [41] explored the therapeutic effects of resveratrol in a mouse model of chronic rhinosinusitis with nasal polyps (CRSwNP) and the mechanism of action. Both eosinophilic infiltration and subepithelial fibrosis were significantly decreased by high-dose resveratrol; the potency of which was similar to that of triamcinolone acetonide.…”

Section: Discussionmentioning

confidence: 99%

Is resveratrol therapeutic when used to treat allergic rhinitis in rats?

Bozdemir¹,

Şahin²,

Altıntoprak³

et al. 2016

CIM

View full text Add to dashboard Cite

TurkeyIs resveratrol therapeutic when used to treat allergic rhinitisinitis in rats?Abstract Purpose: Resveratrol has anti-infective, anti-inflammatory and antioxidant activities. The purpose of this study was to determine the effect of resveratrol in a rat experimental model of allergic rhinitis (AR).Methods: Wistar albino rats were divided into three groups: control (n=7), AR with no treatment (AR+NoTr, n=7) and AR with resveratrol treatment (AR+Res, n=7). For AR+Res, AR was induced and resveratrol given on days 21-28. On day 28, the total blood IgE levels were measured. Allergic symptoms (sneezing, nose-rubbing, eye lacrimation and nasal congestion) were scored on a 0-3 point scale, and histopathological changes in the nasal mucosa were evaluated.Results: Allergic symptom score of AR+NoTr was higher than the other two groups and the score of AR+Res was higher than the control group. Histopathologically, neither ciliary loss nor chondrocyte hypertrophy differed among the three groups; however, vascular congestion, inflammatory and plasma cell numbers, eosinophil and mast cell infiltration and goblet cell numbers were higher and mast cell infiltration was more prominent in AR+NoTr than in AR+Res and control. AR+Res and control did not differ significantly in any histological parameter.In AR+NoTr, nasal mucosa exhibited ciliary loss, squamous epithelial metaplasia, inflammatory cell infiltration, vascular congestion of the lamina propria and goblet cell epithelial metaplasia. In AR+Res, goblet cell metaplasia was focal or absent and infiltration of the lamina propria by inflammatory cells, eosinophils, and plasma cells was reduced relative to AR+NoTr.Conclusion: Allergic symptoms and tissue reactions were reduced by resveratrol treatment in rats with experimentally-induced AR.

show abstract

Resveratrol prevents development of eosinophilic rhinosinusitis with nasal polyps in a mouse model

Abstract: Resveratrol may be useful for the prevention of eosinophilic CRSwNP. A key mechanism of its action is believed to be its anti-inflammatory effect, particularly on eosinophils, by inhibiting the lipoxygenase pathway.

Cited by 40 publications

References 25 publications

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Sinonasal Delivery of Resveratrol via Mucoadhesive Nanostructured Microparticles in a Nasal Polyp Mouse Model

Establishment and verification of a mouse model of nasal wound healing

Is resveratrol therapeutic when used to treat allergic rhinitis in rats?

Contact Info

Product

Resources

About